IBEC researcher Joan Montero authors a paper in Nature Communications which uncovers a key adaptation that melanoma cancer cells use to evade current therapies. This finding might allow physicians to use better drug combinations to improve patient outcomes in the future.
Despite significant advances in cancer diagnosis and treatment, most targeted cancer therapies fail to achieve complete tumor regressions or durable remission. Understanding why these treatments are not always efficient has remained a main challenge for researchers and physicians. Now, Joan Montero from the IBEC and colleagues at Dana-Farber Cancer Institute/Harvard Medical School in USA report in Nature Communications a mechanism that uncovers why some therapies fail to treat melanoma.
Irene Marco explains at BigVan, the scientific section of La Vanguardia journal, how thanks to microfluidics and research based on the use of “organ-on-a-chip” devices, we can go a step forward towards personalized medicine.
Three IBEC projects have been selected to receive funding from “La Marató 2018: Against Cancer.” One of the projects is led by the researcher Pere Roca-Cusachs and the other two are co-led by the researchers Xavier Trepat and Núria Montserrat.
The awarding ceremony took place on October 30 in the Auditorium of the Academy of Medical and Health Sciences of Catalonia and the Balearic Islands. In this edition, over the 188 evaluated projects, 43 have been selected by an international committee of experts in cancer based on their excellence, methodology and relevance. La Marató de TV3, together with Catalunya Ràdio, broadcasts its annual telethon to raise funds for scientific research into various diseases with a different theme each year.
Researchers at the Autonomous University of Barcelona (UAB) and Institute for Bioengineering of Catalonia (IBEC) have revealed a way to effectively deliver a mycobacterium needed for the treatment of bladder cancer in humans –using a formulation based on olive oil.
The researchers have found a way to reduce the natural clumping that occurs when mycobacteria cells, which possess a high content of lipids in their walls, are introduced to the usual aqueous solutions that are used for intravesical instillation in bladder cancer patients. This clumping may interfere with the interaction of the mycobacteria-host cells and negatively influence their antitumor effects.